Introduction: As most patients with ovarian cancer experience multiple remissions and relapses, oncologists must prepare ahead for long-term treatment. While platinum-based regimens are standard of care for platinum-sensitive recurrence, there are circumstances in which platinum rechallenge is not the best approach. These situations include patients with limited sensitivity to platinum; patients with residual toxicity from previous platinum therapy; and patients at risk of developing hypersensitivity reactions. An alternative regimen for these patients is the non-platinum combination of trabectedin + pegylated liposomal doxorubicin (PLD). Areas covered: In this review, case studies are presented to illustrate how careful strategic planning, in terms of therapeutic choices and optimal sequencing, can achieve good outcomes in difficult-to-treat patients. Expert commentary: Advantages with use of trabectedin + PLD in selected patients with platinum-sensitive recurrent ovarian cancer include additional time to recover from platinum-related toxicities, avoidance of hypersensitivity reactions, and the ‘sequence effect’ by which trabectedin may enhance response to next platinum and prolong survival.
Colombo, N., Hardy-Bessard, A., Ferrandina, G., Marth, C., & Romero, I. (2016). Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge. EXPERT REVIEW OF ANTICANCER THERAPY, 16(sup1), 11-19.
Citazione: | Colombo, N., Hardy-Bessard, A., Ferrandina, G., Marth, C., & Romero, I. (2016). Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge. EXPERT REVIEW OF ANTICANCER THERAPY, 16(sup1), 11-19. |
Tipo: | Articolo in rivista - Articolo scientifico |
Carattere della pubblicazione: | Scientifica |
Presenza di un coautore afferente ad Istituzioni straniere: | Si |
Titolo: | Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge |
Autori: | Colombo, N; Hardy-Bessard, A; Ferrandina, G; Marth, C; Romero, I |
Autori: | |
Data di pubblicazione: | 2016 |
Lingua: | English |
Rivista: | EXPERT REVIEW OF ANTICANCER THERAPY |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1080/14737140.2016.1243475 |
Appare nelle tipologie: | 01 - Articolo su rivista |